Prof. Nathalie Chaput-Gras

Prof. Nathalie Chaput-Gras is Co-Founder of Signadori Bio, a Paris-based preclinical biopharmaceutical company pioneering next-generation, off-the-shelf monocyte immunotherapy for solid tumours.
She serves as Professor and Lab Head of the Laboratory for Immunomonitoring in Oncology (LIO) at Gustave Roussy, Europe's leading cancer centre, and is affiliated with the University Paris-Saclay School of Pharmacy.
A world-renowned immuno-oncologist, she holds an Immunology D-index of 68 with over 29,000 citations and received the 2025 Research.com Immunology in France Leader Award.
She co-founded Signadori Bio in 2025 alongside Dr. Jean-Luc Perfettini, translating groundbreaking Gustave Roussy research on p21-driven monocyte reprogramming into a clinical-stage pipeline backed by Sofinnova Partners, Invivo Partners, and Taiho Ventures.
Signadori Bio has raised EUR 11.1 million in seed financing and is advancing lead programme SiB-2101 toward lead candidate nomination, targeting unmet needs in solid tumour treatment.
2136
Prof. Nathalie Chaput-Gras

Company(s)
Industry
Healthtech & Biotech